Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of BI 44847 (Empagliflozin)
NCT02211937Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2007
- Primary completion
- Mar 2007
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum concentration of the analyte in plasma at 48 hours, Area under the concentration-time curve from 0 to the time of the last quantifiable data point at 48 hours and 1 more. Started Jan 2007; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02211937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211937.